Navigation Links
Palatin Technologies and King Pharmaceuticals Report Data Showing,Improvements in Sexual Relationship and Self-Esteem in Patients,with Erectile Dysfunction Treated with Bremelanotide

CRANBURY, N.J., and BRISTOL, Tenn., May 22, 2007 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. and King Pharmaceuticals, Inc. reported today that data from Study 16 and Study 17 of the Phase 2B clinical trial program evaluating bremelanotide in men with erectile dysfunction (ED) were presented yesterday at the American Urological Association (AUA) Annual Meeting (AUA 2007) held in Anaheim, CA. New positive data presented showed that bremelanotide improved both self-esteem and sexual relationship in men with erectile dysfunction (ED). Other positive top line data from the Phase 2B clinical trial program were reported by the companies in November 2006 and at the 9th European Society for Sexual Medicine (ESSM) Congress in Vienna in December 2006.

In order to better understand the effects that bremelanotide may have on improving quality of life and self-esteem, patients in Study 16 were administered the SEAR (Self-Esteem and Relationship), a validated psychological instrument with two major domains: sexual relationship and confidence. The SEAR data were presented at AUA 2007 by Stanley E. Althof, PhD, Professor of Psychology, Case Western Reserve School of Medicine in a session entitled Improvement in Sexual Relationship, Satisfaction, Confidence and Self-Esteem in Erectile Dysfunction Patients Treated with Bremelanotide.

Dr. Althof commented, "Our analysis has shown that treatment with bremelanotide improved both the Self-Esteem and Sexual Relationship domains of the SEAR in non-diabetic ED patients and this was strongly correlated with improvements in erectile function. These results indicate that bremelanotide improves sexual confidence and has the potential to be an important treatment option for patients with ED."

"An increasing focus and attention on the utility of therapy in restoring quality of life and improvements to interpersonal relationships continues to evolve and will driv
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Palatin Technologies and King Pharmaceuticals Announce Plan To Present Results of Bremelanotide Phase 2b Studies in Men With Erectile Dysfunction
2. Neose Technologies to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
3. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
4. Genelabs Technologies Announces Presentation of Data on Non-Nucleoside HCV Polymerase Inhibitor at 20th International Conference on Antiviral Research Meeting
5. Micell Technologies Presents Data on Novel Drug-Eluting Stents
6. OncoGenex Technologies Announces Phase II Data of OGX-011 in Metastatic Breast Cancer at American Association for Cancer Research 2007 Annual Meeting
7. AVAX Technologies Presents Results of Phase I-II M-Vax Trial at Annual Meeting of American Association for Cancer Research
8. Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery of GLP-1 and PYY
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:7/29/2015)... 2015  Medical Care Alert, a leading national provider ... availability of its new HOME & AWAY ELITE mobile ... neck or on the hip, the small two-ounce pendant ... USA using the AT&T Wireless network. ... in mobile and automatic fall detection medical alert systems. ...
(Date:7/29/2015)... , 29. Juli 2015 ... wurde festgestellt, dass die tägliche Einnahme des ... die menschliche Darmflora anreichert und die Darmproduktion ... Die Studie umfasste die tägliche Einnahme von ... in Tablettenform unter Verwendung der patentierten Verabreichungstechnologie ...
(Date:7/29/2015)... , July 29, 2015 ... Novartis transaction closed, CFO Simon Dingemans reveals ... businesses are performing in line with expectations. Ahead of ... commitment to sustainable innovation. The interview and ... MerchantCantos produces in-depth interviews, documentaries and webcasts with ...
Breaking Medicine Technology:New Medical Care Alert Pendant Combines GPS, Cellular Voice, and Automatic Fall Detection 2New Medical Care Alert Pendant Combines GPS, Cellular Voice, and Automatic Fall Detection 3New Medical Care Alert Pendant Combines GPS, Cellular Voice, and Automatic Fall Detection 4Klinischer Nachweis erbracht, dass L. reuteri Probiotikum von Nutraceutix den Darm-Insulinmetabolismus moduliert 2
... MADISON, Conn., Aug 31 The results of the initial ... invasive treatment for varicose veins, will be delivered on Wednesday, September ... Phlebologie in Monaco. The device combines mechanical and chemical modalities to ... Speaking is Steve Elias MD FACS FACPh, Associate Professor of ...
... , , PARIS, ... will present initial results of the CURRENT-OASIS 7 clinical trial at ... SAN, and NYSE: SNY ) and Bristol-Myers Squibb (NYSE: ... bisulfate), were sponsors of the study. , , ...
Cached Medicine Technology:ClariVein(TM) Catheter for Varicose Veins: Clinical Trial Results to be Presented 2New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of PLAVIX(R) in Acute Coronary Syndrome Patients Undergoing Angioplasty 2New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of PLAVIX(R) in Acute Coronary Syndrome Patients Undergoing Angioplasty 3New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of PLAVIX(R) in Acute Coronary Syndrome Patients Undergoing Angioplasty 4New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of PLAVIX(R) in Acute Coronary Syndrome Patients Undergoing Angioplasty 5
(Date:7/29/2015)... Angeles, CA (PRWEB) , ... July 29, 2015 , ... We are privileged to announce ... Keck Medicine of USC as the ninth best ophthalmology hospital in the nation for 2015-2016. ... top 10 American hospitals for ophthalmology. , “It is an honor to be included ...
(Date:7/29/2015)... ... 29, 2015 , ... A June 10, 2015 article from the News-Press, entitled ... importance of having regular skin cancer screenings from an early age. Skin cancer can ... When caught early, skin cancer is rarely fatal; however, if left alone for too ...
(Date:7/29/2015)... ... 2015 , ... TransFlip is an all new dynamic transition pack for FCPX, ... these transitions are easy to apply and modify for any skill-level user. TransFlip includes ... preset styles, kinetic flipping panel animations are just a few clicks away. , TransFlip ...
(Date:7/29/2015)... ... July 29, 2015 , ... " mybody ” was featured ... small, medium and large businesses making an impact in their industry. Andrew Tropeano, the ... how these advanced probiotic skincare products are designed to strengthen the skin’s defense system ...
(Date:7/29/2015)... ... ... Indiana is known for basketball, the boyhood home of Abraham Lincoln, and Santa ... expand across the state. , Ray Kennedy, owner of the Zerorez Indianapolis Region, started ... should double our first year’s revenue. More importantly, we are growing repeat customers, ...
Breaking Medicine News(10 mins):Health News:21 Years & Counting: The USC Eye Institute Ranks in the Top 10 Ophthalmology Hospitals in America 2Health News:21 Years & Counting: The USC Eye Institute Ranks in the Top 10 Ophthalmology Hospitals in America 3Health News:Get Checked for Skin Cancer Early and Often 2Health News:Get Checked for Skin Cancer Early and Often 3Health News:Pixel Film Studios Releases FCPX Transition TransFlip for FCPX 2Health News:Strengthen the Skin’s Defense System from the Inside Out with mybody 2Health News:Zerorez® Announces Plans to Roll Across Indiana—“The Crossroads of America.” 2Health News:Zerorez® Announces Plans to Roll Across Indiana—“The Crossroads of America.” 3
... 78% Take Medications, Yet Just Over 1 in 4 are Aware ... Aug. 11 According to a new study released today by the ... and older have had one or more medical condition and 78 percent ... of the potential impact on driving performance associated with those medications. , ...
... ... Safety and Liquid Nitrogen Application Developments, which follow on from the overwhelming success of ... ... August 10, 2009 -- CryoService Ltd are planning a brand new series of nationwide ...
... , , , ... 10 PAREXEL International Corporation (Nasdaq: PRXL ) today reported ... 2009. The Company has determined the need to correct certain accounting ... below. These changes relate to (1) the ClinPhone Interactive Voice Response ...
... , , LOS ANGELES, ... & GORIN, LLP ( www.KEGLa w yers.com ) ... California courtrooms, likely the only defense firm to do so anywhere in ... rarely successfully presented in Los Angeles courts, as California law places a ...
... SHENZHEN, China, Aug. 10 /PRNewswire-Asia-FirstCall/ -- Mindray Medical,International Limited ... medical devices worldwide announced today its selected unaudited,financial results for the ... Highlights for Second Quarter and First Half 2009, ... million, an increase of, 9.9% ...
... , , FRAMINGHAM, ... HTWR ) (ASX: HIN) today announced that it has entered ... the United States to sell approximately 2.5 million shares of its ... investors have agreed to purchase the shares at a purchase price ...
Cached Medicine News:Health News:Large Majority of Drivers 55 and Older Unaware of Potentially Dangerous Combination of Medications and Driving, Says New AAA Foundation Study 2Health News:Large Majority of Drivers 55 and Older Unaware of Potentially Dangerous Combination of Medications and Driving, Says New AAA Foundation Study 3Health News:CryoService Ltd Liquid Nitrogen Safety Training will Hit the Road Again in October 2009 2Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 2Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 3Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 4Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 5Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 6Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 7Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 8Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 9Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 10Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 11Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 12Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 13Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 14Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 15Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 16Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 17Health News:Los Angeles Criminal Defense Attorneys Secure Insanity Verdicts in Two Southern California Murder Cases 2Health News:Mindray Announces Second Quarter 2009 Financial Results 2Health News:Mindray Announces Second Quarter 2009 Financial Results 3Health News:Mindray Announces Second Quarter 2009 Financial Results 4Health News:Mindray Announces Second Quarter 2009 Financial Results 5Health News:Mindray Announces Second Quarter 2009 Financial Results 6Health News:Mindray Announces Second Quarter 2009 Financial Results 7Health News:Mindray Announces Second Quarter 2009 Financial Results 8Health News:Mindray Announces Second Quarter 2009 Financial Results 9Health News:Mindray Announces Second Quarter 2009 Financial Results 10Health News:Mindray Announces Second Quarter 2009 Financial Results 11Health News:Mindray Announces Second Quarter 2009 Financial Results 12Health News:Mindray Announces Second Quarter 2009 Financial Results 13Health News:Mindray Announces Second Quarter 2009 Financial Results 14Health News:Mindray Announces Second Quarter 2009 Financial Results 15Health News:Mindray Announces Second Quarter 2009 Financial Results 16
Carl Zeiss immersion oils are PCF free. They are quality controlled for two wavelengths of light, Ne=1.518 and Nd=1.515 at 23ºC....
Immersion Oil, 150 cs...
Immersion oils may crystallize on storage. Can be redissolved on heating to 50ºC (1-2 hours)...
Immersion oil for microscopy...
Medicine Products: